Helus Pharma Inc. has announced a significant leadership transition, marking an important milestone in the company's evolution. Co-founders Eric So and Paul Glavine have stepped down from their executive roles but will continue to serve on the Board of Directors. This change reflects the company's readiness to advance its clinical programs and strategic initiatives in the pharmaceutical sector.
Founded as a clinical-stage pharmaceutical company, Helus Pharma is committed to improving mental health treatments through the development of novel serotonergic agonists. The company is currently focused on its proprietary drug candidates, HLP003 and HLP004, which are in various stages of clinical development.
Background
Helus Pharma Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates on the Nasdaq exchange under the ticker HELP. The company is incorporated in Canada and is recognized as an emerging growth entity. Recent filings indicate a series of updates leading to this significant leadership change.
What the Filing Says
The recent filing reveals that Eric So has served as the President and Executive Chairman since the company's inception, while Paul Glavine has held various leadership roles, including Chief Growth Officer. Both co-founders have expressed confidence in the company's current leadership and strategic direction.
"Helus Pharma has reached an important stage in its development, and we believe the Company is well positioned to advance its programs through the next phase of growth," said So and Glavine in a joint statement.
Impact
This transition may significantly affect the company's strategic direction and operational focus. The appointment of Mark Lawson as the new independent Chair of the Board is expected to bring fresh perspectives and leadership experience to Helus Pharma. Lawson, who has over 20 years of experience in private equity and investment banking, has been a board member since November 2020 and will now lead the Board in overseeing the company's growth.
What's Next
The filing does not say what happens next. However, the company continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder in the fourth quarter of 2026.